ipsen Pty Ltd is the Australian affiliate of a global specialty-driven pharmaceutical company with total sales exceeding $1.1 billion in 2012. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by franchises: neurology / Dysport, endocrinology / Somatuline, uro-oncology / Diphereline. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient driven platforms, peptides and toxins. In 2012, R&D expenditure totalled more than $250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees
Likes: 7
Viewed: 5820
source